Concepedia

Joris Vandenbossche

JV

10

Publications

338

Citations

10

H-Index

2011

Active since

Affiliations

Janssen (United States)(Current)

Janssen (Belgium)

Inserm

Erasmus MC

Hospices Civils de Lyon

Joris Vandenbossche is an author at Janssen (United States) specializing in medicine, pharmacology, and viral hepatitis.

ORCID

Top concepts

Publications per year

2011–2023

10

Publications

10

JNJ-56136379, an HBV Capsid Assembly Modulator, Is Well-Tolerated and Has Antiviral Activity in a Phase 1 Study of Patients With Chronic Infection

Fabien Zoulim, Oliver Lenz, Joris Vandenbossche et al. · Gastroenterology · 2020 · 114 citations · Full text

Randomised phase 2 study (JADE) of the HBV capsid assembly modulator JNJ-56136379 with or without a nucleos(t)ide analogue in patients with chronic hepatitis B infection

Harry L.A. Janssen, Jinlin Hou, Tarik Asselah et al. · Gut · 2023 · 53 citations · Full text

Efficacy and safety results of the phase 2 JNJ-56136379 JADE study in patients with chronic hepatitis B: Interim week 24 data

Harry L.A. Janssen, Jinlin Hou, Tarik Asselah et al. · Journal of Hepatology · 2020 · 36 citations

, , +8

Randomized 5‐Treatment Crossover Study to Assess the Effects of External Heat on Serum Fentanyl Concentrations During Treatment With Transdermal Fentanyl Systems

Kenneth Todd Moore, Gayatri Sathyan, Ute Richarz et al. · The Journal of Clinical Pharmacology · 2011 · 28 citations

Pharmacokinetics, Safety and Tolerability of JNJ-56136379, a Novel Hepatitis B Virus Capsid Assembly Modulator, in Healthy Subjects

Joris Vandenbossche, Wolfgang Jessner, Maarten van den Boer et al. · Advances in Therapy · 2019 · 28 citations

, , +8

Rows per page

1–5 of 10